Department of Nuclear Medicine, The Fifth Affiliated Hospital, Sun Yat-Sen University, Guangdong Province, 519000, China.
Guangdong Provincial Key Laboratory of Biomedical Imaging and Guangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital, Sun Yat-Sen University, Guangdong Province, 519000, China.
Eur J Nucl Med Mol Imaging. 2023 Jul;50(8):2305-2318. doi: 10.1007/s00259-023-06183-7. Epub 2023 Mar 14.
Here, we aim to identify a CEACAM5-targeted nanobody and demonstrate its application in positron emission tomography (PET) imaging and near-infrared (NIR) fluorescence imaging in colorectal cancer (CRC).
Immunohistochemistry was applied to verify CEACAM5 expression in CRC and metastatic lymph nodes (mLNs). CEACAM5-targeted nanobodies were obtained by immunization of human CEACAM5 protein in a dromedary, followed by several rounds of phage screenings. Immunofluorescence staining and flow cytometry was carried out to determine the binding affinity of the nanobodies. The nanobodies were radiolabeled by coupling F-SFB for PET imaging of CRC subcutaneous xenografts and lymph node metastasis (LNM). IRDye800CW (IR800) were conjugated to form NIR probes for NIR imaging in CRC subcutaneous models.
CEACAM5 was overexpressed in either human CRC tissues or mLNs. A CEACAM5 targeted nanobody, Nb41 was successfully generated, with excellent in vitro binding properties. Incorporation of albumin binding domain (ABD) did not affect the affinity of Nb41. In vivo imaging showed that both F-FB-Nb41 and F-FB-Nb41-ABD showed obvious accumulation in the tumor. Due to the longer retention in the blood, F-FB-Nb41-ABD enrichment in tumors was significantly delayed but higher compared to F-FB-Nb41. Both F-FB-Nb41 and F-FB-Nb41-ABD showed prominent LNM enrichment. Similarly, the IR800-conjugated nanobodies Nb41-IR800 and Nb41-ABD-IR800 exhibited superior imaging effects in subcutaneous models, while Nb41-ABD-IR800 exhibited higher fluorescence intensity in the tumor accompanied with a remarkedly delay compared to Nb41-IR800.
Collectively, we presented the identification and in vivo validation of a CEACAM5-targeted nanobody and a fused nanobody with an ABD, which enabled to the non-invasive visualization of malignancy of CRC using PET imaging and NIR imaging in subcutaneous models as well as LNM models.
本研究旨在鉴定一种靶向 CEACAM5 的纳米抗体,并展示其在结直肠癌(CRC)正电子发射断层扫描(PET)成像和近红外(NIR)荧光成像中的应用。
采用免疫组织化学法验证 CRC 和转移淋巴结(mLN)中 CEACAM5 的表达。通过对人 CEACAM5 蛋白免疫骆驼,然后进行几轮噬菌体筛选,获得靶向 CEACAM5 的纳米抗体。通过免疫荧光染色和流式细胞术确定纳米抗体的结合亲和力。通过与 F-SFB 偶联对 CRC 皮下异种移植和淋巴结转移(LNM)进行 PET 成像,对纳米抗体进行放射性标记。将 IRDye800CW(IR800)偶联形成 NIR 探针,用于 CRC 皮下模型的 NIR 成像。
CEACAM5 在人 CRC 组织或 mLN 中过度表达。成功生成了一种靶向 CEACAM5 的纳米抗体 Nb41,具有出色的体外结合特性。结合白蛋白结合结构域(ABD)不会影响 Nb41 的亲和力。体内成像显示,F-FB-Nb41 和 F-FB-Nb41-ABD 均在肿瘤部位明显聚集。由于在血液中保留时间更长,F-FB-Nb41-ABD 在肿瘤中的富集明显延迟,但高于 F-FB-Nb41。F-FB-Nb41 和 F-FB-Nb41-ABD 均在 LNM 中明显富集。同样,IR800 缀合的纳米抗体 Nb41-IR800 和 Nb41-ABD-IR800 在皮下模型中表现出优异的成像效果,而 Nb41-ABD-IR800 与 Nb41-IR800 相比,在肿瘤中表现出更高的荧光强度和明显的延迟。
总之,我们鉴定并验证了一种靶向 CEACAM5 的纳米抗体和一种带有 ABD 的融合纳米抗体,可通过 PET 成像和 NIR 成像在皮下模型和 LNM 模型中对 CRC 的恶性程度进行非侵入性可视化。